血脂异常作为心血管疾病的重要危险因素，与动脉粥样硬化、冠心病、脑卒中等多种严重疾病的发生发展紧密相关，严重威胁着人们的健康。近年来，血脂领域的研究不断取得新突破，从新型降脂药物的研发到血脂管理策略的优化，每一项进展都备受关注。北京时间3月28日至30日，备受瞩目的ACC.26学术会议将在美国新奥尔良盛大召开。作为心血管领域的国际盛会，本次大会众多国际研究者发布了针对血脂异常的最新研究成果，POCKETIN特别汇集整理了相关日程，一起来先睹为快！
03月28日
1006. New Frontiers in Lipid Management
北京时间：22:42
EFFICACY AND SAFETY OF OLEZARSEN FOR THE MANAGEMENT OF DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLEDTRIALS
Olezarsen治疗血脂异常的疗效与安全性：随机对照试验的系统评价与荟萃分析
S. Neppala
北京时间：23:18
LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS
脂蛋白(a)靶向治疗对比安慰剂/标准治疗在动脉粥样硬化性心血管疾病中的应用：对主要不良心血管事件、脂蛋白(a)降低及安全性的影响——随机对照试验的系统评价与荟萃分析
N. Lanka
1302. Cardiovascular Disease Prevention 01
北京时间：22:30
REAL-WORLD UTILIZATION AND PERSISTENCE OF LIPID-LOWERING THERAPIES AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI)
经皮冠状动脉介入治疗后降脂治疗的真实世界使用情况与持续性
Muhammad Raffey Shabbir
北京时间：22:30
IMPACT OF LOMITAPIDE ON LIPID PROFILES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
洛美他派对纯合子家族性高胆固醇血症血脂谱的影响：一项系统评价与单组荟萃分析
A. Akoum
北京时间：22:30
EFFICACY AND SAFETY OF RECATICIMAB FOR LDL-C AND LIPOPROTEIN(A) REDUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
瑞卡西单抗降低低密度脂蛋白胆固醇和脂蛋白(a)的疗效与安全性：一项系统评价与荟萃分析
S. Fausto Girón
北京时间：22:30
SGLT2 INHIBITORS, BUT NOT DPP4 INHIBITORS,LOWER LDL-C ANDIMPROVE OUTCOMES IN PATIENTSWITH DIABETES AND CORONARY ARTERY DISEASE
SGLT2抑制剂，而非DPP4抑制剂，可降低糖尿病合并冠状动脉疾病患者的低密度脂蛋白胆固醇并改善结局
A. Theertham
1305. Congenital Heart Disease 01
北京时间：22:30
EXPLORING THE RELATIONSHIP BETWEEN ATRIAL REFRACTORINESS, DYSLIPIDEMIA AND ATRIAL FIBRILLATION IN CHILDREN AND YOUNG PERSONS
探讨儿童与青少年心房不应期、血脂异常及心房颤动之间的关系
S. P. Behere
1310. Vascular Diseases 01
北京时间：22:30
DOSE-RESPONSE RELATIONSHIP AND EFFICACY OF EVINACUMAB FOR REFRACTORY AND GENETIC DYSLIPIDEMIAS A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
依维苏单抗在难治性及遗传性血脂异常中的剂量-反应关系及疗效：随机对照试验的系统评价与荟萃分析
Syed Habib
1323. Heart Failure and Cardiomyopathies 01
北京时间：22:30
GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED/MILDLY REDUCED EF: 5-YEAR OUTCOMES AND EFFECT MODIFICATION BY OBESITY AND ETHNICITY
GLP-1受体激动剂在射血分数降低/轻度降低的心力衰竭中的应用：5年结局及肥胖与种族的效应修饰作用
H. Agarwal
03月29日
1019. Cellular Biology of Atherosclerotic Plaque
北京时间：00:36
OXIDIZED LDL TRIGGERS PYROPTOSIS IN VASCULAR SMOOTH MUSCLE CELLS AND SALIDROSIDE TREATMENT MITIGATES THIS PATHWAY TO IMPROVE PLAQUE STABILITY
氧化低密度脂蛋白触发血管平滑肌细胞发生细胞焦亡，而红景天苷治疗可减轻该通路以改善斑块稳定性
许恒伟 陕西省人民医院
北京时间：00:48
IMPAIRED EFFEROCYTOSIS IN RESPONSE TO LOW-DENSITY LIPID AND LOW SHEAR STRESS IN AN IN-VITROMODEL OF ATHEROSCLEROSIS
在动脉粥样硬化体外模型中，对低密度脂蛋白和低剪切应力应答的胞葬作用受损
Ruben Tapia-Orihuela
1324. CV Team 02
北京时间：00:00
FLORIDA CARDIOVASCULAR QUALITY NETWORK; THE CENTRAL ROLE OF ADVANCED PRACTICE PROFESSIONALS TO ACHIEVE A SUSTAINED TWO YEAR IMPROVEMENT IN CARDIOVASCULAR RISK IN HIGH RISK HYPERLIPIDEMIA PATIENTS
佛罗里达心血管质量网络：高级执业医师在高风险高脂血症患者中实现心血管风险持续两年改善的核心作用
Kim Seals
1325. Featured Fields 02
北京时间：00:00
CHRONOLOGICAL AGING AND PROGRESSION OF CORONARY ARTERY DISEASE: INSIGHTS FROM POOLED IVUS TRIALS OF LIPID-LOWERING THERAPIES
时序性衰老与冠状动脉疾病进展：来自降脂治疗汇总血管内超声试验的见解
A. Damluji
1326. Cardiovascular Disease Prevention 02
北京时间：00:00
THE RELATIONSHIP BETWEEN CYTOKINES AND LIPIDS WITH MRI-DERIVED MEASURES OF CARDIAC MORPHOLOGY IN MEXICAN AMERICANS
墨西哥裔美国人中细胞因子和血脂与磁共振成像衍生的心脏形态测量指标之间的关系
V. O’Brien
北京时间：00:00
EFFECT OF AN EMR-EMBEDDED IN-HOSPITAL CLINICAL PATHWAY ON LIPID MANAGEMENT AFTER ACUTE CORONARY SYNDROME
嵌入电子病历的院内临床路径对急性冠状动脉综合征后血脂管理的影响
Tatsuhiro Kataoka
北京时间：00:00
A SINGLE-CENTER RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN LIPOPROTEIN(A) AND LIPID LEVELS IN A PEDIATRIC POPULATION
脂蛋白(a)与儿童人群血脂水平关联的单中心回顾性研究
Dorota Gruber
1328. Ischemic Heart Diseases 02
北京时间：00:00
RACIAL/ETHNIC AND SEX DISPARITIES IN LDL-C TESTING FREQUENCY POST CORONARY ARTERY BYPASS GRAFTING (CABG): INSIGHTS FROM A LARGE INTEGRATED, DIVERSE HEALTHCARE SYSTEM
冠状动脉旁路移植术后低密度脂蛋白胆固醇检测频率的种族/民族和性别差异：来自一个大型综合性多元化医疗系统的见解
Janine Yang
1332. Coronary, Peripheral and Structural Interventions 02
北京时间：00:00
REFERENCE ZONE LIPID PLAQUE AND TIME TO RESTENOSIS PREDICT NEOATHEROSCLEROSIS ON OCT
参照区脂质斑块和再狭窄时间预测光学相干断层扫描上的新发动脉粥样硬化
Nicholas Olivieri
1337. Complex Clinical Cases: Cardiovascular Disease Prevention 02
北京时间：00:00
LACK OF RESPONSE TO INCLISIRAN IN HIGH-RISK PATIENTS WITH ADVERSE EFFECTS TO TRADITIONAL LIPID-LOWERING THERAPIES
高危患者对英克司兰无反应并对传统降脂治疗产生不良反应
Patricia Machado
1034. Cardiac Imaging Research: From Data to Decision
北京时间：01:42
PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID LOWERING THERAPY USING AI BASED OPTICAL FLOW RATIO: INSIGHTS FROM YELLOW III STUDY
使用基于人工智能的光学血流比评估最大降脂治疗前后非阻塞性冠状动脉病变的生理变化：来自YELLOW III研究的见解
P. Chenniganahosahalli
1038. Drug Therapy in Valvular Heart Disease: Evaluating Evidence for Disease Modification and Outcome Improvement
北京时间：01:30
ASPIRIN THERAPY IN INDIVIDUALS WITH ELEVATED OXIDIZED PHOSPHOLIPIDS AND RISK OF CALCIFIC AORTIC VALVE DISEASE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
阿司匹林治疗在氧化磷脂升高个体中的应用与钙化性主动脉瓣疾病风险：多民族动脉粥样硬化研究
A. C. Razavi
1348. CV Team 03
北京时间：01:30
FROM GRAFT TO GRAPH: REAL WORLD PRACTICES IN LIPID LOWERING AMONG TRANSPLANT PATIENTS
从移植到图谱：移植患者中降脂治疗的真实世界实践
S. F. Weintraub
228. Bold Moves into the Future: The 2026 ACC/AHA Multisociety Guideline For Management of Dyslipidemia
北京时间：02:41
A New Era in Risk Assessment: The PREVENT Calculator in Dyslipidemia Management
风险评估的新纪元：PREVENT计算器在血脂异常管理中的应用
Donald M. Lloyd-Jones
北京时间：03:03
The Risk Continuum: Lipid Management From Start to Finish
风险连续体：从头到尾的脂质管理
Pamela Bowe Morris
1052. Targeting Lp(a) to Reduce Risk
北京时间：03:00
LP(A)-CORRECTED APOB-P/HDL-P RATIO STRONGLY PREDICTS ASCVD EVENTS: UK BIOBANK INSIGHTS
LP(A)-校正的APOB-P/HDL-P比值可强效预测动脉粥样硬化性心血管疾病事件：来自英国生物样本库的见解
E. S. Epstein
北京时间：03:12
LIPOPROTEIN(A), OXIDIZED PHOSPHOLIPIDS AND TENSILE CLOT STRENGTH MEASURED BY THROMBOELASTOGRAPHY IN PATIENTS UNDERGOING PERCUTANEOUS INTERVENTION
接受经皮介入治疗患者的脂蛋白(a)、氧化磷脂与血栓弹力图测定的血栓拉伸强度
Paul Gurbel
1060. ACC Complex Clinical Cases: Cardiovascular Disease Prevention
北京时间：03:48
ACUTE-ONSET CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PRECIPITATED BY PCSK9 INHIBITOR DOSE ESCALATION: A COMPLEX CASE IN DYSLIPIDEMIA MANAGEMENT
由PCSK9抑制剂剂量递增引发的急性发作性慢性炎性脱髓鞘性多发性神经病：一例复杂的血脂异常管理案例
C. Stephenson-Moe
1374. Cardiovascular Disease Prevention 04
北京时间：03:00
LIPID SUBFRACTIONS AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION: A LIPIDOMICS APPROACH TO CARDIOVASCULAR RISK IN THE BRAZILIAN LONGITUDINAL STUDY OF ADULT HEALTH ELSA BRAZIL
脂质亚组分与亚临床动脉粥样硬化进展：巴西成人健康纵向研究中脂质组学方法对心血管风险的研究
L. F. Carvalho
北京时间：03:00
WOMEN ARE LESS LIKELY THAN MEN TO RECEIVE ADD-ON NONSTATIN LIPID-LOWERING THERAPY (LLT) AND TO ADHERE TO LLT: A SYSTEMATIC REVIEW
女性接受附加非他汀类降脂治疗及坚持该治疗的可能性低于男性：一项系统评价
Alejandro Victores
1376. Ischemic Heart Diseases 04
北京时间：03:00
LIPID PROFILES UNDERLIE PROTECTION FROM ATHEROSCLEROSIS SEEN IN PATIENTS WITH ASCENDING THORACIC AORTIC ANEURYSMS
血脂谱是升主动脉瘤患者对动脉粥样硬化具有保护作用的基础
Asanish Kalyanasundaram
北京时间：03:00
PATTERNS AND CHARACTERISTICS OF ASCVD EVENTS IN PATIENTS ≥65 YEARS WITH LP(A) ≥50 MG/DL: PREMATURE, AVERAGE, AND NO EVENTS
65岁及以上脂蛋白(a) ≥50 mg/dL患者动脉粥样硬化性心血管疾病事件的模式与特征：早发、平均发生与无事件
V. T. Le
1380. Coronary, Peripheral and Structural Interventions 04
北京时间：03:00
EFFECT OF LIPID-LOWERING THERAPY ON INTRACORONARY IMAGING ENDPOINTS FOLLOWING PACLITAXEL-COATED BALLOON TREATMENT
降脂治疗对紫杉醇涂层球囊治疗后冠状动脉内影像学终点的影响
Tamara Dijkstra
1385. Complex Clinical Cases: Cardiovascular Disease Prevention 04
北京时间：03:00
ROBUST LP(A) REDUCTION WITH COMBINED TOCILIZUMAB AND INCLISIRAN IN A HIGH-RISK INFLAMMATORY PATIENT
联合托珠单抗与英克司兰在高风险炎症患者中实现脂蛋白(a)的显著降低
Robert Luceri
1069. Next-Generation Lipid Treatement Options
北京时间：04:54
EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING
阿利西尤单抗和英克司兰在临床实践环境中降低低密度脂蛋白胆固醇的有效性
M. Banach
1397. Featured Fields 05
北京时间：04:30
LIPID PROFILES AND FAST FOOD CONSUMPTION PATTERNS AMONG YOUNG AND OLDER U.S. ADULTS: AN NHANES 2008-2018 ANALYSIS
美国年轻与年长成人的血脂谱和快餐消费模式：2008-2018年美国国家健康与营养调查分析
H. Shah
1398. Cardiovascular Disease Prevention 05
北京时间：04:30
FLORIDA CARDIOVASCULAR QUALITY NETWORK: TWO YEAR RESULTS CONFIRM A SUSTAINED IMPROVEMENT IN CARDIOVASCULAR RISK IN HIGH RISK HYPERLIPIDEMIA PATIENTS
佛罗里达心血管质量网络：两年结果证实高风险高脂血症患者心血管风险的持续改善
A. Allen Seals
北京时间：04:30
THE IMPACT OF STATIN THERAPY ON LIPID PROFILES AND ATHEROSCLEROTIC MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A META-ANALYSIS
他汀类药物治疗对系统性红斑狼疮患者血脂谱和动脉粥样硬化标志物的影响：一项荟萃分析
Danielle Howell
北京时间：04:30
LIPOPROTEIN(A) AND OXIDIZED PHOSPHOLIPIDS-APOLIPOPROTEIN B, BIOMARKERS OF RISK IN CARDIAC TRANSPLANT OUTCOMES
脂蛋白(a)和氧化磷脂-载脂蛋白B：心脏移植结局的风险生物标志物
Andrew Kao
1419. Heart Failure and Cardiomyopathies 05
北京时间：04:30
HYPERLIPIDEMIA AS A PREDICTOR OF EPICARDIAL ADIPOSITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED BUT NOT REDUCED EJECTION FRACTION
高脂血症作为射血分数保留而非降低的心力衰竭患者心外膜脂肪量的预测因子
M. C. Volk
233. New Kids on the Block in the Battle Against PAD
北京时间：05:15
Novel Lipid Therapies in PAD
外周动脉疾病中的新型脂质疗法
Naomi M. Hamburg
1084. Evolving Non-Statin Lipid Therapies
北京时间：22:54
LIPID-LOWERING EFFICACY AND SAFETY OF RECATICIMAB IN DYSLIPIDEMIA PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS: A POOLED PATIENT-LEVEL SUBGROUP ANALYSIS
瑞卡西单抗在伴或不伴2型糖尿病的血脂异常患者中的降脂疗效与安全性：一项患者水平汇总的亚组分析
孙燕依 上海交通大学医学院附属瑞金医院
北京时间：23:06
EFFICACY AND SAFETY OF OBICETRABIP IN REDUCING ATHEROGENIC LIPIDS: A SYSTEMATIC REVIEW AND DOSE RESPONSE META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS
Obicetrapib降低致动脉粥样硬化脂质的疗效与安全性：一项系统评价、剂量反应荟萃分析及试验序贯分析
Prutha Pathak
1422. Cardiovascular Disease Prevention 06
北京时间：22:30
EFFECT OF BASELINE LIPID LEVELS OR STATIN USE ON FINERENONE TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY POST HOC ANALYSIS
基线血脂水平或他汀类药物使用对慢性肾脏病合并2型糖尿病患者非奈利酮治疗结局的影响：FIDELITY事后分析
A. Verma
1433. Complex Clinical Cases: Cardiovascular Disease Prevention 06
北京时间：22:30
AGGRESSIVE LIPID LOWERING IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: 29 YEARS EVENT-FREE SURVIVAL AFTER PREMATURE STEMI
杂合子家族性高胆固醇血症的强化降脂治疗：早发ST段抬高型心肌梗死后29年无事件生存
Robert Luceri, MD
北京时间：22:30
SITOSTEROLEMIA: A RARE, UNDERDIAGNOSED GENETIC DYSLIPIDEMIA
谷固醇血症：一种罕见、未被充分诊断的遗传性血脂异常
Boran Mao
267. From Pharm to Table: An Update on Cardiac Prevention Medications
北京时间：23:55
Tasting Menu of the Newest Lipid Medications
最新降脂药物的品鉴菜单
Ashley Arana Waring
4505. Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
北京时间：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
随血脂管理律动：降低动脉粥样硬化性心血管疾病风险的新节奏
Tyler J. Gluckman
北京时间：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
随血脂管理律动：降低动脉粥样硬化性心血管疾病风险的新节奏
Viet T. Le
北京时间：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
随血脂管理律动：降低动脉粥样硬化性心血管疾病风险的新节奏
Erin D. Michos
北京时间：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
随血脂管理律动：降低动脉粥样硬化性心血管疾病风险的新节奏
Pam Taub
3001. Putting the Guidelines into Practice: Building a State-of-the-Art Lipid and Cardiometabolic Clinic
北京时间：07:10
Key Implementation Highlights from the 2026 Guideline on the Management of Dyslipidemia
2026年血脂异常管理指南的关键实施要点
Pamela Bowe Morris
北京时间：07:25
Nuts and Bolts of a Lipid and Cardio-Kidney-Metabolic Clinic
血脂与心脏-肾脏-代谢门诊的基本要素
Anum Saeed
1350. Cardiovascular Disease Prevention 03
北京时间：01:30
RETHINKING RISK THRESHOLDS: LP(A) STRATIFICATION REVEALS STEPWISE RISE IN MORTALITY AND MACE
重新思考风险阈值：脂蛋白(a)分层显示死亡率和主要不良心血管事件呈阶梯式上升
Osman Yousafzai
4002. Make It Standard: Lp(a) Integration For CV Risk Impact
北京时间：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
标准化：Lp(a) 整合对心血管风险的影响
Christie M. Ballantyne
北京时间：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
标准化：Lp(a)整合对心血管风险影响
Keith C. Ferdinand
北京时间：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
标准化：Lp(a)整合对心血管风险的影响
Fatima Rodriguez
402. Driving Impact at the Point of Care: Inside the ACC’s Solution Set Strategy
北京时间：00:55
Driving Urgency in LDL Screening
推动低密度脂蛋白筛查的紧迫性
Timothy A. Dewhurst
03月30日
1446. Cardiovascular Disease Prevention 07
北京时间：00:00
ASSOCIATION BETWEEN LDL-C LOWERING AND REDUCED RISK OF CARDIOVASCULAR EVENTS: AN UPDATED SYSTEMATIC REVIEW AND META-REGRESSION
低密度脂蛋白胆固醇降低与心血管事件风险降低之间的关联：一项更新的系统评价与元回归分析
X. Zhang
1448. Ischemic Heart Diseases 07
北京时间：00:00
THE INCOMPLETE PREVENTION STORY: TRENDS IN LIPID PROFILES AND THERAPY PATTERNS BEFORE FIRST ACUTE MYOCARDIAL INFARCTION IN THE BMC2 REGISTRY
不完全的预防故事：BMC2登记研究中首次急性心肌梗死前血脂谱和治疗模式的趋势
M. Albdewi
1457. Complex Clinical Cases: Cardiovascular Disease Prevention 07
北京时间：00:00
STEPWISE COMBINATION THERAPY ACHIEVING SIGNIFICANT LDL-CHOLESTEROL REDUCTION IN SEVERE HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
逐步联合治疗在重度纯合子家族性高胆固醇血症中实现显著的低密度脂蛋白胆固醇降低
Christine Kong
108. Cardiovascular Update For the Clinician I: A Symposium by Valentin Fuster
北京时间：01:51
Solving Statin Intolerance and Lp(a) Challenges: The Five Advances, Including RNA Agents With Infrequent SC Injections
解决他汀不耐受与脂蛋白(a)挑战：五项进展，包括间歇皮下注射的RNA药物
Robert S. Rosenson
1116. Environment Influences on Prevention
北京时间：01:42
PM2.5 ACCELERATES ATHEROSCLEROSIS VIA ROS-INDUCED LDL OXIDATION AND ENDOTHELIAL PROGENITOR CELL DEPLETION: PROTECTIVE ROLE OF N-ACETYLCYSTEINE
PM2.5通过活性氧诱导的低密度脂蛋白氧化和内皮祖细胞耗竭加速动脉粥样硬化：N-乙酰半胱氨酸的保护作用
Yuqi Cui
1469. Cardiovascular Disease Prevention 08
北京时间：01:30
TRENDS AND DEMOGRAPHIC DISPARITIES IN HYPERTENSION AND DYSLIPIDEMIA-RELATED MORTALITY IN OLDER AMERICAN ADULTS, 1999-2023
1999-2023年美国老年人高血压和血脂异常相关死亡率的趋势与人口统计学差异
R. Ochani
北京时间：01:30
FINDINGS FROM THE LISTEN-LDL-US (LIPID LOWERING THERAPY INSIGHTS PATIENT SURVEY ON TREATMENT EXPERIENCES AND NEEDS IN THE UNITED STATES) STUDY
来自LISTEN-LDL-US（美国降脂治疗患者体验与需求洞察调查）研究的发现
Alejandro Victores
北京时间：01:30
COMPARATIVE EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY WITH OR WITHOUT AI-PLAQUE ANALYSIS AND STRESS TESTING ON LIPID LOWERING AFTER ONE YEAR: A PRIMARY ANALYSIS OF THE DECIDE (AI-DERIVED PLAQUE QUANTIFICATION: CTA AND AI-QCPA FOR DETERMINING EFFECTIVE CAD MANAGEMENT) REGISTRY
冠状动脉CT血管成像联合或不联合人工智能斑块分析及负荷试验对一年后降脂效果的比较：DECIDE（人工智能衍生斑块量化：用于确定有效冠状动脉疾病管理的CTA与AI-QCPA）登记研究的初步分析
Sarah Rinehart
1473. Multimodal Imaging 08
北京时间：01:30
PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY USING AI-BASED MURRAY LAW-DERIVED QUANTITATIVE FLOW RATIO (µFR): INSIGHTS FROM THE YELLOW III STUDY
使用基于人工智能的默里定律衍生的定量血流比评估最大降脂治疗前后非阻塞性冠状动脉病变的生理变化：来自YELLOW III研究的见解
P. Chenniganahosahalli
1480. Complex Clinical Cases: Cardiovascular Disease Prevention 08
北京时间：01:30
WHEN LIPIDS MISLEAD: A CARDIOLOGIST’S DILEMMA IN REFRACTORY HYPERTRIGLYCERIDEMIA
当脂质误导：一位心脏病专家在难治性高甘油三酯血症中的困境
Kristina Golovataya
305. When is Exercise the Risk? And When is It the Rx?
北京时间：03:20
Managing Hyperlipidemia in the Athlete
运动员的高脂血症管理
James S. Guseh
1133. Social Factors Driving Cardiovascular Outcomes
北京时间：03:12
RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND LIPID ABNORMALITIES IN FOOD INSECURE POPULATIONS
食物不安全人群中血糖控制与脂质异常之间的关系
Tina Ting, MPH
1493. Cardiovascular Disease Prevention 09
北京时间：03:00
THE APOB-LDL-C CONTINUUM: INSIGHTS INTO TESTING TRENDS AND DISCORDANCE FROM A LARGE-SCALE LABORATORY STUDY
载脂蛋白B-低密度脂蛋白胆固醇连续谱：来自大规模实验室研究的检测趋势与不一致性的见解
Anjali Bhatla
北京时间：03:00
LDL CHOLESTEROL, NON-HDL CHOLESTEROL, APOLIPOPROTEIN B AND 30-YEAR RISK OF CARDIOVASCULAR DISEASE AMONG HEALTHY WOMEN
健康女性中低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇、载脂蛋白B与30年心血管疾病风险的关系
Ask Nordestgaard
北京时间：03:00
PREVALENCE AND PRACTICE OF LP(A) TESTING IN HIGH RISK POPULATIONS AT THE UNIVERSITY OF KANSAS MEDICAL CENTER
堪萨斯大学医学中心高风险人群中脂蛋白(a)检测的普遍性与实践
P. M. Moriarty
1495. Ischemic Heart Diseases 09
北京时间：03:00
CORONARY CT ANGIOGRAPHY FINDINGS DRIVE LIPID-LOWERING THERAPY INITIATION AND INTENSIFICATION IN CLINICAL PRACTICE
冠状动脉CT血管成像结果推动临床实践中降脂治疗的启动与强化
W. van de Vijver
1504. Complex Clinical Cases: Cardiovascular Disease Prevention 09
北京时间：03:00
HIDING IN PLAIN SIGHT: PARTIAL LIPODYSTROPHY WITH SEVERE DYSLIPIDEMIA, STATIN INTOLERANCE, AND PREMATURE CORONARY ARTERY DISEASE IN A TRIATHLETE
隐藏在明处：一名铁人三项运动员的部分脂肪萎缩伴严重血脂异常、他汀不耐受及早发冠状动脉疾病
C. S. Agu
1506. Complex Clinical Cases: Ischemic Heart Diseases 09
北京时间：03:00
WHEN GAINS BECOME LOSSES: EXOGENOUS TESTOSTERONE AND CARNIVORE DIET LINKED TO SEVERE HYPERLIPIDEMIA AND PREMATURE CORONARY ARTERY DISEASE
当获益转为损失：外源性睾酮与肉食饮食与严重高脂血症及早发冠状动脉疾病相关
Mary Trejo Hernandez
1517. Cardiovascular Disease Prevention 10
北京时间：04:30
THE MI-TO-CVD RATIO IN LIPID-LOWERING TRIALS: EVOLVING PATTERNS AND IMPLICATIONS FOR FUTURE STUDY DESIGN
降脂试验中的心肌梗死与心血管疾病比值：演变模式及对未来研究设计的意义
R. Nair
1521. Multimodal Imaging 10
北京时间：04:30
AI-BASED ANGIOGRAPHY-DERIVED RADIAL WALL STRAIN IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY: INSIGHTS FROM THE YELLOW III STUDY
基于人工智能的血管造影衍生的非阻塞性冠状动脉病变在最大降脂治疗前后径向壁应变：来自YELLOW III研究的见解
P. Chenniganahosahalli
北京时间：04:30
IMPACT OF MAXIMAL LIPID LOWERING THERAPY ON THE PHYSIOLOGICAL DISEASE PATTERN USING AI BASED VIRTUAL µFR PULLBACK CURVE: INSIGHTS FROM THE YELLOW III STUDY
使用基于人工智能的虚拟µFR回撤曲线评估最大降脂治疗对生理疾病模式的影响：来自YELLOW III研究的见解
P. Chenniganahosahalli
北京时间：04:30
INTRACORONARY IMAGING INSIGHTS INTO THE MORPHOLOGY OF CALCIFIED NODULES BEFORE AND AFTER MAXIMAL LIPID LOWERING THERAPY: A SUBSTUDY OF YELLOW III
最大降脂治疗前后钙化结节形态的冠状动脉内影像学见解：YELLOW III研究的子研究
Pruthvi Chenniganahosahalli
1528. Complex Clinical Cases: Cardiovascular Disease Prevention 10
北京时间：04:30
A CASE OF REMARKABLE REDUCTION IN LDL FROM AKKERMANSIA PROBIOTIC
一例阿克曼氏菌益生菌显著降低低密度脂蛋白胆固醇的病例
J. Helali
北京时间：04:30
THE PERFECT STORM: TACKLING THE TRIPLE THREAT OF LIPID DISORDERS, TYPE 1 DIABETES, AND AN INFLAMMATORY DISORDER IN A YOUNG WOMAN
完美风暴：应对年轻女性中脂质紊乱、1型糖尿病和炎症性疾病的三重威胁
J. Hicks
北京时间：04:30
BEATING THE ODDS: ADVANCED LIPID THERAPY ACHIEVES CONTROL IN CHYLOMICRONEMIA
战胜逆境：先进的脂质治疗实现乳糜微粒血症的控制
Flavia Tejada
1538. Heart Failure and Cardiomyopathies 10
北京时间：04:30
TRENDS IN HEART FAILURE AND HYPERLIPIDEMIA-RELATED MORTALITY IN THE UNITED STATES: A RETROSPECTIVE ANALYSIS OF CDC WONDER FROM 1999 TO 2019
美国心力衰竭与高脂血症相关死亡率的趋势：1999年至2019年CDC WONDER数据库的回顾性分析
A. Shabbir
1163. Advancing Lipid Management and Prevention in IHD
北京时间：22:30
ACHIEVED LDL-C IS ASSOCIATED WITH SAPHENOUS VEIN GRAFT PATENCY IN THE NEWTON-CABG CARDIOLINK-5 STUDY
在NEWTON-CABG CARDIOLINK-5研究中，达到的低密度脂蛋白胆固醇水平与大隐静脉桥血管通畅性相关
Michael Szarek
北京时间：22:54
REAL-WORLD GAPS IN PRIMARY PREVENTION AND LIPID CONTROL AMONG PATIENTS PRESENTING WITH THEIR FIRST ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE NCDR CHEST PAIN-MI REGISTRY
首次急性心肌梗死患者在初级预防和血脂控制方面的真实世界差距：来自NCDR胸痛-心肌梗死登记研究的见解
Mohammed Essa
北京时间：23:06
RAPIDLY ESCALATED LIPID-LOWERING THERAPY EFFECTIVENESS IN PLAQUE STABILIZATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)
快速升级的降脂治疗在脂蛋白(a)升高患者中稳定斑块的有效性
Karlis Trusinskis
1164. Expanding Evidence for Nutrient Stimulated Hormone Therapies
北京时间：22:54
EFFECT OF ORFORGLIPRON, A NOVEL ORAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, ON LIPID PANEL AND BLOOD PRESSURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
奥格列龙一种新型口服胰高血糖素样肽-1受体激动剂，对血脂谱和血压的影响：随机对照试验的荟萃分析
S. Kommu
1165. Lipid Control in Real-World Practice
北京时间：22:30
POST-MI LIPID MANAGEMENT: A PRACTICE PATTERN ANALYSIS OF THERAPY ESCALATION AND MONITORING GAPS IN CARE
心肌梗死后血脂管理：治疗升级与护理监测缺口的实践模式分析
S. Khetrapal
北京时间：23:06
REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY
阿托伐他汀/依折麦布固定剂量联合治疗的真实世界降脂疗效及目标达成情况
Byung Gyu Kim
北京时间：23:18
LDL-C LOWERING AND ASSOCIATED RISK REDUCTION OF MYOCARDIAL INFARCTION AND STROKE-RELATED HOSPITALIZATIONS IN PATIENTS WITH ASCVD AND DIABETES
降低低密度脂蛋白胆固醇及其与动脉粥样硬化性心血管疾病和糖尿病患者心肌梗死及卒中相关住院风险降低的关联
R. Jin
1541. Cardiovascular Disease Prevention 11
北京时间：22:30
PREVALENCE AND PATIENT CHARACTERISTICS OF PATIENTS WITH EXTREMELY HIGH ≥ 400 LDL-C LEVELS IN A LARGE INTEGRATED HEALTHCARE SYSTEM
大型综合医疗系统中极高（≥ 400 mg/dL）低密度脂蛋白胆固醇水平患者的患病率及患者特征
J. S. Rana
1552. Complex Clinical Cases: Cardiovascular Disease Prevention 11
北京时间：22:30
WHEN LDL-C LIES - LIPOPROTEIN X MASQUERADING AS SEVERE HYPERCHOLESTEROLEMIA
当低密度脂蛋白胆固醇说谎时——脂蛋白X伪装成严重高胆固醇血症
R. Zhang
1562. Heart Failure and Cardiomyopathies 11
北京时间：22:30
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
GLP-1受体激动剂对肥胖合并2型糖尿病患者轻度降低或保留射血分数的心力衰竭的影响：一项系统评价与荟萃分析
B. Jeswani
276. Featured Clinical Research III
北京时间：01:35
Role Of Screening With Coronary Computed Tomography Angiography In Lipid Management In An Asymptomatic Chinese Population: A Community-based, Parallel-group, Open-label, Randomized Clinical Trial (RESPECT2)
冠状动脉CT血管造影筛查在无症状中国人群血脂管理中的作用：一项基于社区的、平行组、开放标签、随机临床试验（RESPECT2）
郭翔 中国人民解放军东部战区总医院
1471. Ischemic Heart Diseases 08
北京时间：01:30
LIPID-LOWERING EFFICACY AND SAFETY OF OBICETRAPIB: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Obicetrapib的降脂疗效与安全性：一项随机对照试验的荟萃分析
Mariana Adieb
4014. Elevated Lp(a): Implications For Patient Risk Assessment
北京时间：03:45
Elevated Lp(a): Implications For Patient Risk Assessment
升高的脂蛋白(a)：对患者风险评估的意义
Payal Kohli
北京时间：03:45
Elevated Lp(a): Implications For Patient Risk Assessment
升高的脂蛋白(a)：对患者风险评估的意义
Sanjay Kaul
03月31日
1179. Improved Detection of ACS and CAD: Tests & Biomarkers
北京时间：00:24
CIRCULATING PLASMA MICRORNA PANEL FOR THE DETECTION OF LIPID-RICH CORONARY PLAQUES IN PATIENTS WITH EARLY-ONSET CORONARY ARTERY DISEASE.
用于检测早发冠状动脉疾病患者富脂质冠状动脉斑块的血浆微小RNA组合
Evija Kanašniece
1180. Linking Lipid Metrics to CVD Risks
北京时间：00:00
CARDIOVASCULAR EVENTS IN PEOPLE WITH NORMAL LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS BUT DISCORDANTLY HIGH LEVELS OF SMALL/MEDIUM LDL PARTICLES
低密度脂蛋白胆固醇水平正常但小/中密度低密度脂蛋白颗粒水平不一致偏高的个体的心血管事件
Amand Schmidt
北京时间：00:24
BEYOND LDL CHOLESTEROL: TG/HDL-C RATIO AS A MARKER OF CARDIOVASCULAR RISK IN PEOPLE LIVING WITH HIV
超越低密度脂蛋白胆固醇：甘油三酯/高密度脂蛋白胆固醇比值作为HIV感染者的心血管风险标志物
Kathleen Ebersol
北京时间：00:48
IMPACT OF LDL-C AND APOLIPOPROTEIN B LEVEL DISCORDANCE AND ASSOCIATED LIPOPROTEIN PARTICLE ALTERATIONS ON CARDIOVASCULAR OUTCOMES IN A LARGE PRIMARY PREVENTION POPULATION
低密度脂蛋白胆固醇与载脂蛋白B水平不一致及相关脂蛋白颗粒改变对大规模一级预防人群心血管结局的影响
Yuan Du 中国医学科学院阜外医院
1565. Cardiovascular Disease Prevention 12
北京时间：00:00
EFFICACY AND SAFETY OF ONGERICIMAB IN PATIENTS WITH DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
昂戈瑞西单抗在血脂异常患者中的疗效与安全性：随机对照试验的系统评价与荟萃分析
Basel Abdelazeem
北京时间：00:00
SAFETY AND EFFICACY OF SEQUENTIAL HIGH INTENSITY LIPID-LOWERING (SHILL) THERAPY FOR ATTAINMENT OF LDL-C GOAL AFTER ACUTE CORONARY SYNDROMES
序贯高强度降脂疗法在急性冠状动脉综合征后达到低密度脂蛋白胆固醇目标的安全性与有效性
A. K. Pradhan
1576. Complex Clinical Cases: Cardiovascular Disease Prevention 12
北京时间：00:00
UNVEILING FAMILIAL SITOSTEROLEMIA: A SILENT CULPRIT BEHIND HYPERLIPIDEMIA IN AN ASYMPTOMATIC 28 YEAR-OLD MALE
揭示家族性谷固醇血症：一名无症状28岁男性高脂血症背后的隐匿元凶
K. Arora
361. What is the Risk of Lowering Cholesterol? Addressing Patient Concerns Regarding Lipid-Lowering Therapies
北京时间：01:18
Lipid-Lowering Therapies and HbA1c: Will Lowering My Cholesterol Give Me Diabetes?
降脂治疗与糖化血红蛋白：降低胆固醇会让我得糖尿病吗？
Erica Sarah Spatz
北京时间：01:28
Supplements and Cholesterol: What is the Role of OTCs in Lipid Management?
补充剂与胆固醇：非处方药在血脂管理中的作用是什么？
Luke Laffin
1588. Cardiovascular Disease Prevention 13
北京时间：01:30
BEYOND STATINS IN ACUTE CORONARY SYNDROME—AN UPDATED META-ANALYSIS ON PCSK9 INHIBITORS AND THEIR IMPACT ON LIPID CONTROL, PLAQUE BURDEN, AND CLINICAL OUTCOMES
超越他汀，聚焦急性冠状动脉综合征——关于PCSK9抑制剂及其对血脂控制、斑块负荷和临床结局影响的最新荟萃分析
A. Singla
北京时间：01:30
LDL CHOLESTEROL AND CARDIOVASCULAR RISK ACROSS OBESITY AND METABOLIC SYNDROME PHENOTYPES: INSIGHTS FROM THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
低密度脂蛋白胆固醇与心血管风险在肥胖及代谢综合征不同表型中的差异：来自多民族动脉粥样硬化研究的见解
Beshoy Iskander
北京时间：01:30
EFFICACY OF INCLISIRAN FOR MORTALITY AND CARDIOVASCULAR EVENT PREVENTION ON PATIENTS WITH ELEVATED LDL CHOLESTEROL: AN UPDATED META-ANALYSIS
英克司兰对低密度脂蛋白胆固醇升高患者死亡率和心血管事件预防的有效性：一项更新的荟萃分析
Arthur Petrucci
366. Investigative Horizons III
北京时间：03:21
Durability Of Enlicitide For Lipid Lowering: On-treatment Analysis Of Data From CORALreef Lipids And CORALreef HeFH Trials
Enlicitide降脂的持久性：来自CORALreef Lipids和CORALreef HeFH试验的治中数据分析
Ann Navar
POCKETIN 将挑选重点研究，就已发布结果邀请专家陆续解读
POCKETIN接受投稿，我们将为撰稿作者提供该研究的过往详细资料，资料包括：原文、演讲幻灯、官方新闻、演讲视频等素材。并根据稿件质量支付稿费。
稿件将发表在POCKETIN、心关注微信公众号上，并发表在国际期刊《翳望》（ISSN 2709-9105）上。同时，稿件将作为供稿提供给合作单位。
投稿请联系：zhengsisi@medicaltelescope.cn 郑思思
如发现文内有误请联系我们
来源：ACC.26
POCKETIN
ACC.26
由苏州工业园区东方华夏心血管健康研究院和医望共同发起的POCKETIN项目将依托人工智能学术跟踪系统，为全国广大心血管医师带来及时全面的报道。
项目得到了医师报、梅斯医学、365医学网、健康界、中华医学信息导报、心关注、医心、严道医声网等单位的大力支持。
▼更多精彩内容，请长按二维码▼
1. 相关学术信息由医望自主研发的人工智能学术跟踪机器人提供。
2. 相关学术信息由医望提供的医学翻译机器人完成翻译后邀请临床医师进行再次校对。
3. 如有内容上的不准确请微信联系我们（zhengsisi@medicaltelescope.cn）
4. POCKETIN引入人工智能大语言模型，携手专业编辑团队，开启会议速递全新体验。
热门跟贴